Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsRanbaxylaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to
    • Super Six: Top chart picks for November 05

      Super Six: Top chart picks for November 05

      Kunal Saraogi of Equityrush advises buying Apollo Hospitals Enterprises with a target of Rs 1190 and Mahindra & Mahindra Financial Services with a target of Rs 316.

    • Buy Ranbaxy, IRB Infra: Vishal Malkan

      Buy Ranbaxy, IRB Infra: Vishal Malkan

      Vishal Malkan of malkansview.com recommends buying Ranbaxy Laboratories and IRB Infra.

    • Buy Ranbaxy Laboratories, says Sukhani

      Buy Ranbaxy Laboratories, says Sukhani

      Sudarshan Sukhani of s2analytics.com advises buying Ranbaxy Laboratories at current levels.

    • Hold Ranbaxy Laboratories, says Prakash Agarwal

      Hold Ranbaxy Laboratories, says Prakash Agarwal

      According to Prakash Agarwal, Equity Analyst at CIMB, one may hold Ranbaxy Laboratories.

    • Buy Lupin above Rs 1400, says CK Narayan

      Buy Lupin above Rs 1400, says CK Narayan

      CK Narayan, Managing Director at Growth Avenues is of the view that one may buy Lupin above Rs 1400.

    • Buy Ranbaxy; sell Rel Cap, CESC, Adani Ent: Meghana Malkan

      Buy Ranbaxy; sell Rel Cap, CESC, Adani Ent: Meghana Malkan

      Meghana V Malkan of malkansview.com recommends selling Adani Enterprises with a target of Rs 475 and CESC with a target of Rs 748.

    • Bull's Eye: Buy Lupin, HDFC; short HDIL, Reliance Capital

      Bull's Eye: Buy Lupin, HDFC; short HDIL, Reliance Capital

      Meghana V Malkan, malkansview.com advises buying Ranbaxy Labs for a target price of Rs 615 and selling Reliance Capital for a target price of Rs 495.

    • Jyotivardhan Jaipuria neutral on pharma space

      Jyotivardhan Jaipuria neutral on pharma space

      Jyotivardhan Jaipuria, Head of Research, BofA ML is neutral on pharma space.

    • Buy Ranbaxy Laboratories, says Manas Jaiswal

      Buy Ranbaxy Laboratories, says Manas Jaiswal

      Manas Jaiswal of manasjaiswal.com recommends buying Ranbaxy Laboratories as the stock may touch Rs 680 in next two to three trading sessions.

    • Hold Ranbaxy Lab; target Rs 750-770: Akshata Deshmukh

      Hold Ranbaxy Lab; target Rs 750-770: Akshata Deshmukh

      Akshata Deshmukh, Chief Strategist-Trading at Networth Stock Broking is of the view that one may hold Ranbaxy Laboratories with a target of Rs 750-770.

    • Stay with Ranbaxy Laboratories: Hemen Kapadia

      Stay with Ranbaxy Laboratories: Hemen Kapadia

      Hemen Kapadia of KR Choksey Securities is of the view that one may hold Ranbaxy Laboratories.

    • Hold Ranbaxy Laboratories, says Ashu Madan

      Hold Ranbaxy Laboratories, says Ashu Madan

      Ashu Madan of Religare Securities is of the view that one may hold Ranbaxy Laboratories.

    • Add Ranbaxy Laboratories, target Rs 650-660: Hemant Thukral

      Add Ranbaxy Laboratories, target Rs 650-660: Hemant Thukral

      Hemant Thukral of Aditya Birla Money recommends adding Ranbaxy Laboratories as the stock may head towards Rs 650-660.

    • Short Ranbaxy Labs, banks: Sushil Kedia

      Short Ranbaxy Labs, banks: Sushil Kedia

      According to Sushil Kedia of CIMB, one may short Ranbaxy Laboratories and banking stocks like Bank of Baroda, Punjab National Bank, State Bank of India and even ICICI Bank.

    • Sell Ranbaxy; target Rs 270: Ranjit Kapadia

      Sell Ranbaxy; target Rs 270: Ranjit Kapadia

      Ranjit Kapadia, pharma analyst of Centrum Broking suggests selling Ranbaxy Laboratories with a target Rs 270.

    • Super Six stocks you can bet on March 14

      Super Six stocks you can bet on March 14

      Hemen Kapadia of KR Choksey Securities advises selling Ranbaxy Laboratories with a target of Rs 349 and Mcleod Russel (India) with a target of Rs 278.

    • Here are stocks to focus on March 11

      Here are stocks to focus on March 11

      Following are the stocks that CNBC-TV18‘s research team wants you to focus on - ICICI Bank, Maruti Suzuki, Reliance Industries, Tata Power, Reliance Infra, HCL Info , Jet Airways, Gati, Ranbaxy, Autoline Ind.

    • Short Ranbaxy Laboratories: Sudarshan Sukhani

      Short Ranbaxy Laboratories: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may short Ranbaxy Laboratories as the stock may head lower.

    • Top 10 stocks to focus on March 10

      Top 10 stocks to focus on March 10

      According to CNBC-TV18‘s research team following are the stocks to focus on Dr Reddy's, BPCL, Ranbaxy, Dishman Pharma, Bank of Baroda, Ashok Leyland, Jaiprakash Assoc, Crompton Greaves, Eicher Motors and Infotech Ent.

    • Avoid Ranbaxy; prefer Cipla, Biocon: Sharmila Joshi

      Avoid Ranbaxy; prefer Cipla, Biocon: Sharmila Joshi

      Sharmila Joshi of sharmilajoshi.com is of the view that one may avoid Ranbaxy Laboratories and prefer Biocon, Ipca Laboratories and Cipla from the pharmaceutical space.

    • Anish Damania neutral on Ranbaxy Laboratories

      Anish Damania neutral on Ranbaxy Laboratories

      Anish Damania of IDFC Securities is neutral on Ranbaxy Laboratories. "Newsflow continues to remain negative," he adds,

    • Remain invested in Ranbaxy Laboratories: SP Tulsian

      Remain invested in Ranbaxy Laboratories: SP Tulsian

      SP Tulsian of sptulsian.com is of the view that one may remain invested in Ranbaxy Laboratories.

    • Buy Ranbaxy Labs: Sudarshan Sukhani

      Buy Ranbaxy Labs: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Ranbaxy Laboratories.

    • Avoid Ranbaxy Laboratories: Phani Sekhar

      Avoid Ranbaxy Laboratories: Phani Sekhar

      According to Phani Sekhar of Angel Broking, one may avoid Ranbaxy Laboratories.

    • Avoid Ranbaxy Labs, Jaiprakash Asso: Sudarshan Sukhani

      Avoid Ranbaxy Labs, Jaiprakash Asso: Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one may avoid Jaiprakash Associates and Ranbaxy Laboratories.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347